Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019058 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy in Treating Patients With Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00019058: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019058 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019058, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pentoxifylline and hydroxyurea may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus pentoxifylline and hydroxyurea in treating patients who have high-grade astrocytoma or glioblastoma.
Interventions
- RADIATION radiation therapy
- DRUG chemotherapy
- DRUG hydroxyurea
- DRUG pentoxifylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 1995-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019058
The ClinicalTrials.gov registry entry for NCT00019058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which radiation therapy is the first listed.
NCT00019058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019058 about?
NCT00019058 is a clinical study titled "Radiation Therapy in Treating Patients With Glioblastoma". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pentoxifylline and hydroxyurea may make tumor cells more sensitive to radiation therapy. PURPOSE: Phase I trial to study the effectiveness of radiation therapy plus pentoxifylline and hydroxyurea in treating p...
What is the current status of trial NCT00019058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 1995-04.
What interventions are being tested in trial NCT00019058?
The interventions under investigation include: radiation therapy (RADIATION), chemotherapy (DRUG), hydroxyurea (DRUG), pentoxifylline (DRUG).
Who is sponsoring clinical trial NCT00019058?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.